All In Biotech

Drug Trial Radar · NCT01622569

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Last checked: Nov 19, 2026Latest source record: Dec 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Nov 19, 2013

Primary completion

Aug 6, 2015

Study completion Oct 1, 2015

Sponsor

Lead sponsor
Optinose US Inc.Industry
Sponsor type
Industry
First posted
Jun 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral nasal polyposis. Two co-primary endpoints will be used in the study: reduction of nasal congestion/obstruction symptoms at the end of Week 4 of the double-blind treatment phase measured by the 7 day average instantaneous AM diary symptom scores, and reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by the Lildholdt scale score measured by nasoendoscopy.

Conditions

  • Bilateral Nasal Polyposis

Interventions

  • Fluticasone PropionateDrug

    Delivered via Optinose Exhalation Delivery System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction SymptomsTime frame: Baseline, Week 4 of the double-blind treatment phase
  2. Change in Total Polyp GradeTime frame: Baseline, Week 16 of the double-blind treatment phase

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • SC Clinical Research, Inc.

    Tucson, Arizona

  • Kern Allergy and Medical Research, Inc.

    Bakersfield, California

  • Central California Clinical Research

    Fresno, California

  • Allergy & Asthma Specialists Medical Group

    Huntington Beach, California

  • California Allergy & Asthma Medical Group, Inc.

    Los Angeles, California

  • Choc PSF, AMC, Division of AA & I

    Orange, California

  • California Allergy and Asthma Palmdale

    Palmdale, California

  • Peninsula Research Associates, Inc.

    Rolling Hills Estates, California

  • California Medical Clinic for Headache

    Santa Monica, California

  • Asthma & Allergy Associates, P.C.

    Colorado Springs, Colorado

  • Colorado ENT & Allergy

    Colorado Springs, Colorado

  • Colorado Allergy and Asthma Centers, P.C.

    Denver, Colorado

  • University of South Florida Asthma, Allergy & Immunology

    Tampa, Florida

  • NU Feinberg School of Medicine Depart. of Otolaryngology-Head & Neck Surgery

    Chicago, Illinois

  • Chicago ENT

    Chicago, Illinois

  • Northeast Medical Research Associates, Inc

    North Dartmouth, Massachusetts

  • The Center for Pharmaceutical Research, P.C.

    Kansas City, Missouri

  • Clinical Research Group of Montana, PLLC

    Bozeman, Montana

  • Coastal Ear, Nose and Throat, LLC

    Neptune City, New Jersey

  • Montefiore Medical Center

    The Bronx, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Optimed Research

    Columbus, Ohio

  • Allergy, Asthma & Clinical Research Center

    Oklahoma City, Oklahoma

  • Vital Prospects Clinical Research Institute

    Tulsa, Oklahoma

  • National Allergy, Asthma & Urticaria Centers of Charleston, P.A.

    North Charleston, South Carolina

  • AARA Research Center

    Dallas, Texas

  • Ear Nose and Throat Associates of Texas

    Frisco, Texas

  • ENTTEX

    Plano, Texas

  • EVMS Depart. Of Otolaryngology

    Norfolk, Virginia

  • Allergy, Asthma & Sinus Center, S.C.

    Greenfield, Wisconsin

  • Ottawa Allergy Research Corporation

    Ottawa, Ontario, Canada

  • CHUM Hôtel-Dieu

    Montreal, Quebec, Canada

  • Dr. Jaime Del Carpio

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.